Journal
MEDICAL MOLECULAR MORPHOLOGY
Volume 46, Issue 1, Pages 14-19Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s00795-012-0002-z
Keywords
DNA-dependent catalytic subunit (DNA-PKcs); Lymphocyte enhancer factor 1 (LEF-1); Novel interaction partner; Colon adenocarcinoma cell; Thymus; Glutathione-S-transferase pull-down assay; Mass spectrometry
Categories
Funding
- JSPS KAKENHI Grant [24592567]
- Promotion and Mutual Aid Corporation for Private Schools of Japan
- Fujita Health University Research Fund
- Grants-in-Aid for Scientific Research [24590234, 24590264, 24592567] Funding Source: KAKEN
Ask authors/readers for more resources
Lymphocyte enhancer factor 1 (LEF1), a member of the LEF/T-cell-specific factor (TCF) family of the high mobility group domain transcription factors, acts downstream in canonical Wnt signaling. Aberrant transactivation of LEF1 contributes to the tumorigenesis of colonic neoplasms, sebaceous skin tumors, and lymphoblastic leukemia. LEF1-associated proteins are crucial for regulating its transcriptional activity. In this study, glutathione-S-transferase pull-down assay and mass spectrometry enabled identification of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel interaction partner for LEF1. The interaction between LEF1 and DNA-PKcs was confirmed using in vivo co-immunoprecipitation. Furthermore, double immunofluorescence observations showed that LEF1 and DNA-PKcs colocalized in the nuclei of colon adenocarcinoma cell lines. Identification of the interaction between LEF1 and DNA-PKcs may provide clues for a novel therapy for cancer treatment as well as for understanding LEF1-mediated transcriptional regulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available